IP Library Patent Application 14351304
Patent Application
App. No. 14/351,304

METHODS AND COMPOSITIONS FOR RAPID TRANSBUCCAL DELIVERY OF ACTIVE AGENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/351,304
Abstract

A method of rapid transbuccal delivery of an active agent into the bloodstream is provided. The method can include providing a pharmaceutical composition comprising the active agent, resin and a volatile solvent and, optionally, water. In some embodiments, the method achieves a Tmax 60 minutes or less, an onset of therapeutic effect of 60 minutes or less, and/or achieves therapeutic serum levels of the active agent within 60 minutes or less. Related compositions also are provided.

Claims (24)

1 . A method for rapid transbuccal delivery of an active agent into the bloodstream, comprising bucally administering to a subject in need thereof, a pharmaceutical composition comprising (i) a pharmaceutically active agent, (ii) a resin, (iii) a volatile solvent, and optionally (iv) water.

2 . The method of claim 1 , wherein the method results in a Tmax of the active agent selected from the group consisting of less than 60 minutes, less than 45 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, or less than 5 minutes.

3 . The method of claim 1 , wherein the method results in an onset of therapeutic effect within a time period selected from the group consisting of within 60 minutes or less, within 45 minutes or less, within 30 minutes or less, within 20 minutes or less, within 10 minutes or less, within 5 minutes or less, or sooner.

4 . The method of claim 1 , wherein the method results in therapeutic serum levels of the active agent within a time period selected from the group consisting of within 60 minutes or less, within 45 minutes or less, within 30 minutes or less, within 20 minutes or less, within 10 minutes or less, within 5 minutes or less, or sooner.

5 . The method of claim 1 , wherein the active agent is systemically active.

6 . The method of claim 1 , wherein the active agent is selected from the group consisting of nicotine, scopolamine, ondansetron, granisetron, zolmitriptan, dihydroergotamine, sumatriptan, rizatriptan, fentanyl, lidocaine, cocaine, benzocaine, alprazolam, clonazepam, lorazepam, diazepam, estazolam, apomorphine, risperidone.

7 . The method of claim 1 , wherein the active agent is selected from the group consisting of buprenorphine, naloxone, flumazenil, tadalafil, vardenafil, sildenafil, sildenafil mesylate, dolasetron, palonsetron, triazolam, naratriptan, ketorolac, ibuprofen, diclofenac, ketoprofen, flurbiprofen, etololac, naproxen, meclofenamate, indocin, meloxicam, nabumetone, oxaprozin, prioxicam, sulindac, tolmetin, celecoxib, astemizole, terfenadine, cimetidine, loratadine, desloratidine, cetirizine, morphine, hydromorphine, levorphanol, meperidine, oxycodone, oxymorphone, propanolol, calcitriol, and methylphenidate.

8 . The method of claim 1 , wherein the active agent is selected from the group consisting of ondansetron, granisetron, zolmitriptan, dihydroergotamine, sumatriptan, rizatriptan, fentanyl, cocaine, alprazolam, clonazepam, lorazepam, diazepam, estazolam, apomorphine, risperidone, buprenorphine, naloxone, flumazenil, tadalafil, vardenafil, sildenafil, sildenafil mesylate, dolasetron, palonsetron, triazolam, naratriptan, diclofenac, etololac, meclofenamate, indocin, meloxicam, nabumetone, oxaprozin, prioxicam, sulindac, tolmetin, celecoxib, loratadine, desloratidine, cetirizine, morphine, hydromorphine, levorphanol, meperidine, oxycodone, oxymorphone, propanolol, calcitriol, and methylphenidate.

9 . The method of claim 1 , wherein the resin comprises a benzoin gum or mastic gum.

10 . The method of claim 1 , wherein the composition contains about 1%-25% resin.

11 . The method of claim 1 , wherein the composition further comprises water.

12 . The method of claim 1 , wherein the composition comprises 1-40% v/v water.

13 . The method of claim 1 , wherein the composition contains about 17% to 24% resin.

14 . The method of claim 1 , wherein the volatile solvent comprises ethanol.

15 . The method of claim 1 , wherein the composition further comprises a penetration enhancer.

16 . The method of claim 15 , wherein the penetration enhancer is selected from menthol and peppermint oil.

17 . The method of claim 1 , wherein the composition is applied in the form of a paste, a liquid, a semi-solid, a gel, a suspension and an emulsion.

18 . The method of claim 1 , further comprising the step of allowing the volatile solvent to evaporate, thereby forming a hydrophobic film on the mucosa that comprises resin and active agent.

19 . A pharmaceutical composition for rapid transbuccal delivery of an active agent into the bloodstream, comprising (i) a pharmaceutically active agent, (ii) a resin, (iii) a volatile solvent, and optionally (iv) water.

20 . The composition of claim 19 , wherein the active agent is selected from nicotine, scopolamine, ondansetron, granisetron, zolmitriptan, dihydroergotamine, sumatriptan, rizatriptan, fentanyl, lidocaine, cocaine, benzocaine, alprazolam, clonazepam, lorazepam, diazepam, estazolam, apomorphine, risperidone.

21 . The composition of claim 19 , wherein the active agent is selected from buprenorphine, naloxone, flumazenil, tadalafil, vardenafil, sildenafil, sildenafil mesylate, dolasetron, palonsetron, triazolam, naratriptan, ketorolac, ibuprofen, diclofenac, ketoprofen, flurbiprofen, etololac, naproxen, meclofenamate, indocin, meloxicam, nabumetone, oxaprozin, prioxicam, sulindac, tolmetin, celecoxib, astemizole, terfenadine, cimetidine, loratadine, desloratidine, cetirizine, morphine, hydromorphine, levorphanol, meperidine, oxycodone, oxymorphone, propanolol, calcitriol, and methylphenidate.

22 . The composition of claim 19 , wherein the active agent is selected from ondansetron, granisetron, zolmitriptan, dihydroergotamine, sumatriptan, rizatriptan, fentanyl, cocaine, alprazolam, clonazepam, lorazepam, diazepam, estazolam, apomorphine, risperidone, buprenorphine, naloxone, flumazenil, tadalafil, vardenafil, sildenafil, sildenafil mesylate, dolasetron, palonsetron, triazolam, naratriptan, diclofenac, etololac, meclofenamate, indocin, meloxicam, nabumetone, oxaprozin, prioxicam, sulindac, tolmetin, celecoxib, loratadine, desloratidine, cetirizine, morphine, hydromorphine, levorphanol, meperidine, oxycodone, oxymorphone, propanolol, calcitriol, and methylphenidate.

23 . The composition of claim 19 , wherein the resin comprises a benzoin gum or mastic gum.

24 . The composition of claim 19 , further comprising 1-40% v/v water.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 046087 FRAME: 0363. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 21, 2018
From: JALEVA PHARMACEUTICALS, LLC
To: ADVANCED RESIN THERAPEUTICS, INC.
Reel/Frame 046407/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2018
From: JAVELA PHARMACEUTICALS, LLC
To: ADVANCED RESIN THERAPEUTICS, INC.
Reel/Frame 046087/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BATTAGLIA, ALEX
To: JALEVA PHARMACEUTICALS, LLC
Reel/Frame 033434/0716 →